Notes on "Characteristics of gadolinium-DTPA complex: A potential NMR contrast agent"

American Journal of Roentgenology

Volumn 190, Issue 6, 2008, Pages 1433-1434

  Runge, Val M ^a  

^a SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

Contrast media; DTPA; Gadopentetate dimeglumine; MRI

Indexed keywords

GADOLINIUM PENTETATE MEGLUMINE; LANTHANIDE; PENTETIC ACID; PROTON;

BLADDER; BRAIN EDEMA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST; DRUG EXCRETION; DRUG RESEARCH; DRUG SAFETY; DRUG STABILITY; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETISM; MEDICAL LITERATURE; NEUROIMAGING; NONHUMAN; NOTE; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TUMOR DIFFERENTIATION; URINARY EXCRETION;

ANIMALS; CONTRAST MEDIA; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; RATS;

EID: 44849110545     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.07.3549     Document Type: Note

References (15)

1. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR 1984; 142:619-624
2. Bui-Mansfield LT. Top 100 cited AJR articles at the AJR's centennial. AJR 2006; 186:3-6
3. Weinmann HJ, Schuhmann-Giampieri G, Schmitt-Willich H, Vogler H, Frenzel T, Gries H. A new lipophilic gadolinium chelate as a tissue-specific contrast medium for MRI. Magn Reson Med 1991; 22:233-237
4. Staks T, Schuhmann-Giampieri G, Frenzel T, Weinmann HJ, Lange L, Platzek J. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers. Invest Radiol 1994; 29:709-715
5. Runge VM, Stewart RG, Clanton JA, et al. Work in progress: potential oral and intravenous paramagnetic NMR contrast agents. Radiology 1983; 147:789-791
6. Runge VM, Clanton JA, Lukehart CM, Partain CL, James AE Jr. Paramagnetic agents for contrast-enhanced NMR imaging: a review. AJR 1983; 141:1209-1215
7. Weinmann HJ, Speck U, Mutzel W. Gadolinium DTPA, a potential NMR contrast material: efficacy, pharmacokinetics, and tolerance in animals (abstr 675). RSNA 1983. Oak Brook, IL: Radiological Society of North America, 1983
8. Carr DH, Brown J, Bydder GM, et al. Intravenous chelated gadolinium as a contrast agent in NMR imaging of cerebral tumours. Lancet 1984; 1:484-486
9. Runge VM, Clanton JA, Price AC, et al. Dyke Award: Evaluation of contrast-enhanced MR imaging in a brain-abscess model. Am J Neuroradiol 1985; 6:139-147
10. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of Gd-DTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR 1984; 16:167-172
11. Carr DH, Brown J, Bydder GM, et al. Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. AJR 1984; 143:215-224
12. Knopp MV, Balzer T, Esser M, Kashanian FK, Paul P, Niendorf HP. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use. Invest Radiol 2006; 41:491-499
13. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol 2006; 41:206-212
14. Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 2007; 42: 139-145
15. Kramer H, Michaely HJ, Matschl V, Schmitt P, Reiser MF, Schoenberg SO. High-resolution magnetic resonance angiography of the lower extremities with a dedicated 36-element matrix coil at 3 Tesla. Invest Radiol 2007; 42:477-483